Stocks · News reference
Filed: 2026-11-09 AccNo: 0001213900-26-117610 Size: 1 MB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 9.01: Financial Statements and Exhibits
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
iSpecimen Inc. has completed the acquisition of two artificial intelligence products from Foldlab AI Ltd. to enter the AI-powered disease intelligence market.
iSpecimen Inc. stockholders have approved a proposal authorizing a reverse stock split at a ratio between 1-for-10 and 1-for-100.
iSpecimen Inc. has expanded its marketplace to include next-day delivery of prospectively collected healthy donor whole blood and announced plans to develop AI-powered search capabilities for its inventory.
Stock Market Today: S&P 500, Dow Futures Fall as Oil Tops $99 Despite Trump’s Price Drop Prediction— ASML, NVS, CASY in Focus
iSpecimen surged 27.9% premarket on a $4.5M Foldlab AI asset deal; CEA Industries led gainers, while Focus Universal plunged 51.2%.
On September 4, 2026, iSpecimen Inc., a Delaware corporation (the "Company"), entered into an Asset Purchase Agreement (the "Agreement") with Foldlab AI Ltd., a company organized under the laws of